Metabolic targeting of neuroblastoma, an update

This publication has 44 references indexed in Scilit:

• Both Enantiomers of 2-Hydroxyglutarate Modulate the Metabolism of Cultured Human Neuroblastoma Cells
  Neurochemical Research, 2024
• Targeting c‐Myc transactivation by LMNA inhibits tRNA processing essential for malate‐aspartate shuttle and tumour progression
  Clinical and Translational Medicine, 2024
• DFMO inhibition of neuroblastoma tumorigenesis
  Cancer Medicine, 2024
• Deep analysis of neuroblastoma core regulatory circuitries using online databases and integrated bioinformatics shows their pan-cancer roles as prognostic predictors
  Discover Oncology, 2021
• Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy againstMYCN‐amplified neuroblastoma
  International Journal of Cancer, 2020
• Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer
  Cell Metabolism, 2020
• The genetic tumor background is an important determinant for heterogeneous MYCN‐amplified neuroblastoma
  International Journal of Cancer, 2016
• AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport
  International Journal of Cancer, 2013
• Hypoxia signalling controls metabolic demand
  Current Opinion in Cell Biology, 2007
• Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck
  Cancer Chemotherapy and Pharmacology, 1992